Colorectal cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• TP53 6
• KRAS 56
• PD-1 108
• BRAF 36
• EGFR 32
• PD-L1 26
• PI3K 2
• STAT3 0
• CTNNB1 1
• AKT 0
• RAS 31
• HER2 38
• mTOR 1
• MAPK 1
• VEGF 14
• ERK 0
• STING 0
• NRF2 0
• PPAR 0
• CTLA-4 16
• HIF-1 0
• COX-2 5
• JNK 0
• AMPK 0
• MYC 0
• PTEN 1
• YAP 0
• GPX4 0
• NRAS 8
• IL-6 0
• JAK 0
• MET 7
• PARP 1
• CXCR4 0
• TNF 0
• NLRP3 0
• BCL-2 0
• HSP90 0
• PIK3CA 2
• GLP-1 1
• HDAC 2
• METTL3 0
• CDK4/6 2
• MEK 1
• CD47 1
• FGFR 0
• BRCA1 1
• NTRK 1
• B7-H3 5
• EZH2 0
• FAK 1
• HMGB1 0
• TROP2 4
• MUC1 2
• ATM 2
• IDO1 1
• IL-1 0
• PCSK9 3
• PINK1 0
• SHP2 0

24 of 4,665 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R43

  Novel macrophage repolarization therapy for colorectal cancer

  Panorama Research, Inc.· Sunnyvale, United States· US$387,240 awarded in fiscal year 2026· until Aug 2027

• NIH NIAID · R01

  Impact of bacterial phenotypic variation on phage resistance

  Institute for Systems Biology· Seattle, United States· US$874,085 awarded in fiscal year 2026· until Aug 2031

• NIH NINR · R01

  Community Health Centers Achieving Metrics and Primed for Success

  University of Pennsylvania· Philadelphia, United States· US$762,815 awarded in fiscal year 2026· until Jun 2031

• NIH NCI · K99

  Developing and Piloting a Multilevel Intervention to Address Nutritional Needs in the Outpatient Oncology Setting

  Yale University· New Haven, United States· US$168,290 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · R01

  The role of IL-9 in gastric metaplasia and carcinogenesis

  Saint Louis University· Saint Louis, United States· US$2,541,122 awarded in fiscal year 2026· until Aug 2030

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Glycoanalytics-guided discovery of novel biomarkers and therapeutic glycoenzyme inhibitors for cancer (GLYCOANALYTICS)

  I3s - Instituto de Investigacao e Inovacao Em Saude Da Universidade Do Porto· Porto, Portugal· EU contribution €207,183· until Aug 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unravelling Glycosylation Codes in Cancer at the Molecular Level: An Interdisciplinary Approach for the Dissection of the Recognition Features of CD44 by Galectins and Selectins (GLYCODECD44)

  Asociacion Centro de Investigacion Cooperativa En Biociencias Cic Biogune· Derio Vizcaya, Spain· EU contribution €194,075· until Aug 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  GUT-commensal Strain for Cancer Assessment and Notification (GUT-SCAN)

  Vib Vzw· Zwijnaarde - Gent, Belgium· EU contribution €200,400· until Mar 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Ion channelome of solid tumours: Novel immunotherapy targets for cancer-specific mRNA and drug delivery (ION-CANDEL)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Germany· EU contribution €217,965· until Jan 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN-JD

  Target mining for the development of therapeutics against pathogen-induced cancers (TagTIC)

  Paris-Lodron-Universitat Salzburg· Salzburg, Austria· EU contribution €4,281,580· until Dec 2031· 9 countries

  The disease is named only in the funder's project summary, not in the title.

10 of 990 running projects, newest first. Listed amounts together: US$548.0m + €233.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Cryptosporidium Infection and Human Colorectal Cancer

  NCT04332705· Lille Catholic University· Updated 6 Nov 2026

  “No other patients could be included within the time frame.”Registry text, quoted unchanged. Source

• Terminated

  CT-95 in Advanced Cancers Associated With Mesothelin Expression

  NCT06756035· Context Therapeutics Inc.· Updated 5 Nov 2026

  “The study was halted prematurely and will not resume; participants are no longer receiving intervention or undergoing evaluations. The termination was not due to any safety or efficacy concerns.”Registry text, quoted unchanged. Source

• Withdrawn

  ctDNA and Organ Preservation/Pathologic CR in Rectal Cancer

  NCT05629442· Massachusetts General Hospital· Updated 4 Nov 2026

  “Funding issues”Registry text, quoted unchanged. Source

• Terminated

  KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer

  NCT05985109· Peking University Cancer Hospital & Institute· Updated 3 Nov 2026

  “The study was stopped early due to lack of efficacy.”Registry text, quoted unchanged. Source

• Suspended

  Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

  NCT07011550· M.D. Anderson Cancer Center· Updated 2 Nov 2026

  “PI Request”Registry text, quoted unchanged. Source

• Suspended

  A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma

  NCT04111172· Thomas Jefferson University· Updated 28 Oct 2026

  “Protocol is with FDA review, waiting for funding to be released”Registry text, quoted unchanged. Source

• Terminated

  Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

  NCT04868877· Merus B.V.· Updated 26 Oct 2026

  “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will have access to treatment outside of this trial.”Registry text, quoted unchanged. Source

• Terminated

  A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors

  NCT06364696· Astellas Pharma Inc· Updated 23 Oct 2026

  “Company's strategic decision”Registry text, quoted unchanged. Source

• Terminated

  The Impact of Laparotomy and Analgesia Methods on Diaphragm

  NCT06403540· Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization· Updated 22 Oct 2026

  “The study was terminated prematurely because the planned sample size could not be achieved due to insufficient participant recruitment.”Registry text, quoted unchanged. Source

• Suspended

  EXtended CriteriA Treatment for LIver Metastases and Heavy Tumour BURden

  NCT04840186· Oslo University Hospital· Updated 22 Oct 2026

  “Not enough patients”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• ABCSG R07 Rectal Cancer Registry

  NCT07780305· Austrian Breast & Colorectal Cancer Study Group· Source

• A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

  NCT07488676· Astellas Pharma Global Development, Inc.· Source

• Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines

  NCT04535401· National Cancer Institute (NCI)· Source

• Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).

  NCT04895722· Merck Sharp & Dohme LLC· Source

• Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.

  NCT03869892· Institut de Recherches Internationales Servier· Source

• A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

  NCT05672524· Memorial Sloan Kettering Cancer Center· Source

• Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy

  NCT07715903· National Cancer Institute (NCI)· Source

• Video-based Project to Improve Colonoscopy Quality in Lower-Volume Clinicians

  NCT07934381· Indiana University· Source

• Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

  NCT06218914· AstraZeneca· Source

• Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)

  NCT04595747· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 134
• Organoids 108
• Mendelian Randomization Analysis 51
• CRISPR-Cas Systems 34
• Gene Expression Profiling 338
• Sequence Analysis, RNA 30
• Whole Genome Sequencing 22
• Exome Sequencing 26
• Proteomics 107
• Metabolomics 92
• Mass Spectrometry 42
• Flow Cytometry 113
• Immunohistochemistry 208
• Liquid Biopsy 36
• Circulating Tumor DNA 120
• Xenograft Model Antitumor Assays 432
• Positron-Emission Tomography 38
• Magnetic Resonance Imaging 196
• Machine Learning 211
• Deep Learning 142
• Cohort Studies 318
• Genome-Wide Association Study 66

• Urothelial Carcinoma in Lynch Syndrome: Clinical and Molecular Insights From a Large Multicenter Cohort.

  JCO Precis Oncol, Nov 2026

• Tobacco and Opium Use and Risk of Liver and Colorectal Cancer Mortality: Analysis of the Golestan Cohort Study.

  Cancer Epidemiol Biomarkers Prev, Nov 2026

• Automated Clinical Decision Support and Electronic Health Record Tracking of Patients With Adenomas Found on Colonoscopy.

  JAMA Netw Open, Nov 2026

• Dietary supplement use throughout the colorectal cancer disease trajectory: a prospective cohort study.

  Support Care Cancer, Oct 2026

• Comorbidity patterns and their associations with performance status and treatment receipt in breast and colorectal cancers in a multiethnic Asian setting: a latent class analysis.

  Support Care Cancer, Oct 2026

• Associations of food processing and dietary risk factors with colorectal cancer incidence in the NIH-AARP Diet and Health Study: A cohort study.

  PLoS Med, Oct 2026

• Living alone and risk of mortality from all-cause and 15 specific causes-a nationally representative cohort study of US adults.

  Int J Epidemiol, Oct 2026

• Association between postoperative bowel symptoms and social isolation in patients with rectal cancer: the moderating effects of social support and psychological resilience.

  Front Public Health, Oct 2026

• Platelet P2Y12 inhibitor use and risk of colorectal cancer incidence and colorectal cancer-related mortality: a Swedish registry-based cohort study.

  BMC Gastroenterol, Oct 2026

• UK national analysis of colonoscopy quality in inflammatory bowel disease surveillance: a National Endoscopy Database (NED) cohort study.

  J Crohns Colitis, Oct 2026

See which targets of this disease your abstract mentions, and go to the people working on them.